Utility of Gene Expression Profiling Score Variability to Predict Clinical Events in Heart Transplant Recipients

Mario C. Deng,1,15,16 Barbara Elashoff,2 Michael X. Pham,3,4 Jeffrey J. Teuteberg,5 Abdallah G. Kfoury,6 Randall C. Starling,7 Thomas P. Cappola,8 Andrew Kao,9 Allen S. Anderson,10 William G. Cotts,11 Gregory A. Ewald,12 David A. Baran,13 Roberta C. Bogaev,14 Khurram Shahzad,15 David Hiller,2 James Yee,2 and Hannah A. Valantine,16

Background. Gene expression profiling test scores have primarily been used to identify heart transplant recipients who have a low probability of rejection at the time of surveillance testing. We hypothesized that the variability of gene expression profiling test scores within a patient may predict risk of future events of allograft dysfunction or death.

Method. Patients from the IMAGE study with rejection surveillance gene expression profiling tests performed at 1- to 6-month intervals were selected for this cohort study. Gene expression profiling score variability was defined as the standard deviation of an individual’s cumulative test scores. Gene expression profiling ordinal score (range, 0–39), threshold score (binary value=1 if ordinal score ≥34), and score variability were studied in multivariate Cox regression models to predict future clinical events.

Results. Race, age at time of transplantation, and time posttransplantation were significantly associated with future events in the univariate analysis. In the multivariate analyses, gene expression profiling score variability, but not ordinal scores or scores over threshold, was independently associated with future clinical events. The regression coefficient P values were <0.001, 0.46, and 0.773, for gene expression profiling variability, ordinal, and threshold scores, respectively. The hazard ratio for a 1 unit increase in variability was 1.76 (95% CI, 1.4–2.3).

Discussion. The variability of a heart recipient’s gene expression profiling test scores over time may provide prognostic utility. This information is independent of the probability of acute cellular rejection at the time of testing that is rendered from a single ordinal gene-expression profiling test score.

Keywords: Transplant, Tests, Risk factors, Prognosis, Molecular diagnostics.

This study was supported by XDx.
Dr. Deng has received grant support, consulting fees, and honorarium from XDx. Ms Elashoff has received consulting fees from XDx. Dr. Pham has received grant support from XDx. Dr. Teuteberg has received grant support from XDx and has served on an advisory board to XDx. Dr. Kfoury has received grant support, consulting fees, and honorarium from XDx. Dr. Starling has received grant support from XDx. Dr. Cappola has received grant support from XDx and Celladon. A patent on gene expression assays to diagnose and track cardiac allograft rejection arising from independent research is pending. Dr. Cappola is one of the inventors. Dr. Kao has received grant support, consulting fees, and honorarium from XDx. Dr. Anderson has received grant support from XDx. Dr. Cotts has received grant support from XDx. Dr. Ewald has received grant support from XDx. Dr. Baran has received grant support from XDx. Dr. Bogaev has received grant support, consulting fees, and financial support for a Texas Heart Institute CME conference from XDx. Dr. Shahzad has received grant support from XDx. Dr. Hiller is an employee in XDx, and Dr. Yee is an employee and owns equity in XDx. Dr. Valantine has received grant support from XDx and has served on an advisory board to XDx.
1 University of California, Los Angeles, CA.
2 XDx Inc., Brisbane, CA.
3 Stanford University Medical Center, Stanford, CA.
4 VA Palo Alto Health Care System, Palo Alto, CA.
5 University of Pittsburgh Medical Center, Pittsburgh, PA.
6 Intermountain Medical Center and Intermountain Healthcare, Salt Lake City, UT.
7 Cleveland Clinic, Cleveland, OH.
8 Hospital of the University of Pennsylvania, Philadelphia, PA.
9 Mid America Heart Institute, Saint Luke’s Hospital, Kansas City, MO.
10 University of Chicago Medical Center, Chicago, IL.
11 Northwestern University, Chicago, IL.
12 Washington University School of Medicine, St. Louis, MO.
13 Newark Beth Israel Medical Center, Newark, NJ.
14 Texas Heart Institute, Houston, TX.
15 Columbia University, New York City, NY.
16 Address correspondence to: Mario Deng, M.D., F.A.C.C., F.E.S.C., Advanced Heart Failure/Mechanical Support/Heart Transplant, David Geffen School of Medicine at UCLA, Ronald Reagan UCLA Medical Center, 100 Medical Plaza Drive, Suite 630 Los Angeles, CA 90095. E-mail: mdeng@mednet.ucla.edu

Received 8 July 2013. Revision requested 30 July 2013. Accepted 30 September 2013.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited.

The work cannot be changed in any way or used commercially.

Copyright © 2014 by Lippincott Williams & Wilkins
ISSN: 0041-1337/14/0000-00
DOI: 10.1097/01.tp.0000443897.29951.cf

Transplantation • Volume 00, Number 00, Month, 2014 www.transplantjournal.com | 1
The standard care of adult heart transplant recipients has included surveillance for rejection with serial endomyocardial biopsies (1–3). Because of the risks and discomforts associated with the biopsy procedure, a noninvasive gene expression profiling test (AlloMap) of peripheral blood was developed to identify heart transplant recipients who have a low probability of rejection at the time of surveillance testing (4–6). We have noticed an association of low variability of gene expression profiling scores within an individual and the clinical stability of the individual (7). Therefore, we hypothesized that the variability of gene expression profiling scores within individuals may predict risk of future allograft events.

To test our hypothesis, we utilized the IMAGE (Invasive Monitoring Attenuation by Gene Expression Profiling) study database, which provided independently adjudicated clinical outcome events observed during surveillance of 602 heart transplant recipients (8). In IMAGE, recipients at least 6 months posttransplantation were randomized 1:1 to either surveillance with routine biopsy or gene expression profiling testing. The patients assigned to gene expression profiling underwent a surveillance biopsy only if the gene expression profiling score was equal to or above the specified threshold of 34. A primary outcome event was defined as an episode of rejection with hemodynamic compromise, graft dysfunction due to other causes, death, or retransplantation. Over a median of 19 months of observation, 297 patients monitored with gene expression profiling and 305 patients monitored with biopsies had similar 2-year cumulative rates of events (14.5% and 15.3%, respectively; hazard ratio with gene expression profiling=1.04; 95% confidence interval, 0.67–1.68) (8).

**RESULTS**

The demographics of the study cohort (N=369) were representative of the features of the parent IMAGE population (n=602) (Table 1). The cohort was predominantly white (80%) men (83%), 54 years of age at the time of transplantation. Study related surveillance began after 12 months posttransplantation in 86% of the cohort.

**Within Patient Gene-Expression Profile Scores and Variability**

The cohort had a mean of 4.4 (SD, ±1.7) gene expression profiling tests and a mean ordinal score of 30.9 (SD, ±0.7) (see Table S1 and Figure S1, SDC, http://links.lww.com/TP/A924). The gene expression profiling variability was 1.0 (SD, ±0.8); 74 patients (20%) had variability less than 0.5, 160 patients (43%) had variability greater than 1.0, 65 patients (18%) had variability greater than 1.5, and 26 patients (7%) had variability greater than 2.0. The variability was 1.6 (SD, ±1.4) units for the event and 1.0 (SD, ±0.7) units for the no events

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>IMAGE population (N=602)</th>
<th>Multivariate analysis study cohort* (N=369)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr: mean±SD</td>
<td>54.1±12.8</td>
<td>54±12.9</td>
</tr>
<tr>
<td>Male sex, no. (%)</td>
<td>493 (82%)</td>
<td>305 (83%)</td>
</tr>
<tr>
<td>Race or ethnic group, no. White (%)</td>
<td>468 (78%)</td>
<td>294 (80%)</td>
</tr>
<tr>
<td>Indication for cardiac transplantation, no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>257 (43%)</td>
<td>160 (43%)</td>
</tr>
<tr>
<td>Nonischemic cardiomyopathy</td>
<td>307 (51%)</td>
<td>185 (50%)</td>
</tr>
<tr>
<td>Other</td>
<td>38 (6%)</td>
<td>24 (7%)</td>
</tr>
<tr>
<td>Interval between transplantation and randomization, no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6–12 mo</td>
<td>88 (15%)</td>
<td>52 (14%)</td>
</tr>
<tr>
<td>13–36 mo</td>
<td>412 (68%)</td>
<td>264 (72%)</td>
</tr>
<tr>
<td>37–60 mo</td>
<td>101 (17%)</td>
<td>52 (14%)</td>
</tr>
<tr>
<td>Cytomegalovirus status, no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donor and recipient positive</td>
<td>237 (39%)</td>
<td>138 (37%)</td>
</tr>
<tr>
<td>Donor and recipient negative</td>
<td>91 (15%)</td>
<td>47 (13%)</td>
</tr>
<tr>
<td>Donor positive and recipient negative</td>
<td>137 (23%)</td>
<td>98 (27%)</td>
</tr>
<tr>
<td>Donor negative and recipient positive</td>
<td>108 (18%)</td>
<td>77 (21%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>29 (5%)</td>
<td>9 (2%)</td>
</tr>
<tr>
<td>Use of ventricular assist device before transplantation, no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Induction therapy (any), no. (%)</td>
<td>352 (58%)</td>
<td>220 (60%)</td>
</tr>
<tr>
<td>Immunosuppressive therapy, no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>162 (27%)</td>
<td>94 (25%)</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>436 (72%)</td>
<td>280 (76%)</td>
</tr>
<tr>
<td>Mycophenolate mofetil or mycophenolic acid</td>
<td>486 (81%)</td>
<td>306 (83%)</td>
</tr>
<tr>
<td>Prednisone</td>
<td>271 (45%)</td>
<td>168 (46%)</td>
</tr>
<tr>
<td>Left ventricular ejection fraction at first study visit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean±SD</td>
<td>60±6.3</td>
<td>60.6±6.4</td>
</tr>
<tr>
<td>No. of events, no. (%)</td>
<td>67 (11%)</td>
<td>30 (8%)</td>
</tr>
</tbody>
</table>

Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
The univariate analyses revealed that nonwhite race, younger age at time of transplantation, and earlier time posttransplantation at study entry were significantly associated with a higher risk of events (Table 2). A nonwhite was 2.9 times more likely to have an event than a white. Sex, number of rejection episodes experienced in the first year and cytomegalovirus serologic status were not significantly associated with events. The significant risk factors were included in the multivariate models below.

### Base Clinical Risk Factors Model

The univariate analyses revealed that nonwhite race, younger age at time of transplantation, and earlier time posttransplantation at study entry were significantly associated with a higher risk of events (Table 2). A nonwhite was 2.9 times more likely to have an event than a white. Sex, number of rejection episodes experienced in the first year and cytomegalovirus serologic status were not significantly associated with events. The significant risk factors were included in the multivariate models below.

### Multivariate Models of Gene Expression Profiling Test Information to Predict Future Clinical Events

Among the multivariate models, only gene expression score variability was significantly predictive of future clinical events (regression coefficient, \(P < 0.001\); Table 3). Gene expression score variability had the lowest estimated information loss (Akaike information criterion (9)) and a predictive accuracy (concordance index) of 0.69 (95% CI, 0.61–0.76). Gene expression score variability was significant even when controlling for gene expression ordinal score (\(P < 0.001\); see Table S2, SDC, http://links.lww.com/TP/A924. The C-index for the base clinical risk factors was 0.68 (95% CI, 0.59–0.78).

The potential clinical utility of the variability score is illustrated in four cases from the IMAGE study (Fig. 1). The hazard ratio associated with the variability score and adjusted

### Table 2. Univariate Cox proportional hazards regression analyses of features associated with clinical events

<table>
<thead>
<tr>
<th>Independent variable</th>
<th>Regression coefficient</th>
<th>(P)</th>
<th>Hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>-0.07</td>
<td>0.83</td>
<td>0.9 (0.5–1.7)</td>
</tr>
<tr>
<td>Race: nonwhite</td>
<td>1.05</td>
<td>&lt;0.001</td>
<td>2.9 (1.8–4.7)</td>
</tr>
<tr>
<td>Age at time of transplant (log year)</td>
<td>-2.57</td>
<td>&lt;0.001</td>
<td>0.64 (0.50–0.82) for a 30-year-old versus a 20-year-old</td>
</tr>
<tr>
<td>Time posttransplant (log days)</td>
<td>-2.39</td>
<td>0.005</td>
<td>0.69 (0.53–0.89) for (12 mo vs. 18 mo)</td>
</tr>
<tr>
<td>No. rejection episodes in the first year</td>
<td>0.049</td>
<td>0.72</td>
<td>1.1 (0.8–1.4) for (30 mo vs. 36 mo)</td>
</tr>
<tr>
<td>&gt;&gt;Cytomegalovirus (CMV) serologic status (ordinal: 0 to 3: D-/R-, D-/R+, D+/R+, D+/R-)</td>
<td>0.09</td>
<td>0.48</td>
<td>1.1 (0.9–1.4)</td>
</tr>
</tbody>
</table>

- **a** Clinical events of rejection with hemodynamic compromise, graft dysfunction due to other causes, death, or retransplantation.
- **b** Hazard ratio: values less than 1 indicate risk decreases as variable increases; the associated regression coefficient is negative.
- **c** Hazard ratio: values less than 1 indicate risk decreases as variable increases; the associated regression coefficient is negative.
- **d** Hazard ratio: values less than 1 indicate risk decreases as variable increases; the associated regression coefficient is negative.

### Table 3. Multivariate models to predict future clinical events

<table>
<thead>
<tr>
<th>Cox proportional hazards regression results of surveillance information added to base clinical model</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regression coefficient (SE)</td>
</tr>
<tr>
<td>-----------------------------</td>
</tr>
<tr>
<td>Base clinical model(c)</td>
</tr>
<tr>
<td>Gene expression profiling test score variability: (standard deviation of all previous gene expression profiling ordinal scores since study entry)(d)</td>
</tr>
<tr>
<td>Gene expression profiling test ordinal score (0–39)(d)</td>
</tr>
<tr>
<td>Gene expression profiling test threshold score (\geq34)</td>
</tr>
</tbody>
</table>

- **a** Clinical events of rejection with hemodynamic compromise, graft dysfunction due to other causes, death, or retransplantation.
- **b** Race, younger age at time of transplantation, and earlier time posttransplantation were the variables included in the Base Clinical Model.
- **c** Hazard ratio: values less than 1 indicate risk decreases as variable increases; the associated regression coefficient is negative.
- **d** Uses transformed gene expression profiling scores. If \(x\) is the AlloMap gene expression profiling ordinal score, we use \(y=2.451(\log(x/(40-x))−0.234)\).
for base clinical risk factors was applied to estimate the probability of future events. The variability score is time varying: for example, in patient B, the variability score is 1.17 at visit 3 and 1.10 at visit 4. Only one example variability score is applied to project the probability of an event in each illustration.

**Patient A**

This white man, transplanted at age 57, was 15 months posttransplant at the time of study entry. Patient A had relatively high ordinal scores (35, 35, 36, 36, and 35); because the scores exceeded the nominal threshold (>34), each
triggered a per protocol endomyocardial biopsy. Patient A did not have biopsy-proven rejection in association with his 34 or higher scores (biopsy grades of 0, 0, 1R, 0 and 1R, respectively (10)). At visit 5, his score variability (0.49) was at the 20th percentile of the study cohort. Based on the multivariate model, patient A with this low variability of gene expression profiling scores had a relatively low probability (2.6%) of a clinical event in the future 12 months from visit 5, although each of his individual ordinal scores exceeded the nominal threshold of 34, which indicated increased risk of moderate or severe (≥grade 2R) acute cellular rejection. This case illustrates that a relatively higher probability of acute cellular rejection associated with an ordinal score 34 or higher (i.e., a 6% to 10% positive predictive value, established from the CARGO population study) may coexist with a relatively low probability of future clinical events. The probability of future clinical events is adjusted for the patient’s underlying clinical risk factors in this model. The risk for future events (defined clinically, without requirement of histologic evidence of rejection) based on the variability of an individual’s gene expression scores may be independent and uncoupled from the risk of acute cellular rejection (defined by histology) based on single gene expression profiling ordinal scores at the time of testing.

**Patient B**

This white man, transplanted at age 34, was 15 months posttransplant at study entry. His ordinal scores (26, 23, 31, 23, and 33) render a higher variability score (1.10 at visit 4, which is at the 64th percentile of the population) compared with patient A. Patient B’s overall higher risk of having a future event (11.5%) after visit 4 is due to his younger age at time of transplantation (age 34) and his higher gene expression profiling score variability compared with patient A. Patient B went on to incur a clinical event of hemodynamic compromise without rejection about 4 months after his visit 4. Six months later (~day 1050 posttransplant), he experienced another episode of hemodynamic compromise with histologic evidence of grade 3A acute cellular rejection.

**Patient C**

This African American woman, transplanted at age 57, was 16 months posttransplant at study entry. Her ordinal scores were 24, 26, 26, and 28. Her low score variability (0.46) at visit 4 was similar to that of patient A. The multivariate model yields a net 12-month probability of a future event (7.1%) in patient D is similar to that of patient C (7.8%) and higher than patient A (2.6%). His gene expression profiling variability score was 1.34, which is at the 77th percentile of the study cohort. Patient D went on to incur a clinical event of rejection with hemodynamic compromise, 3 months after his visit 5.

**DISCUSSION**

The above anecdotal cases help to illustrate the potential use of gene expression profiling variability to predict the probability of future clinical events in heart transplant recipients. For example, a recipient predicted to be at low risk for future events may become a candidate for further minimization of his/her immunosuppressive maintenance regimen. Conversely, an individual predicted to be at higher risk for future events may receive further evaluation to detect possible underlying causes of the variability such as overlooked infections or noncompliance to medications. Our analyses so far have not enabled us to define the specific causes of a high variability of gene expression profiling scores.

Future mechanistic studies, using a larger number of cases, should focus on identifying individual gene pathways associated with global score variability, to further understand the relationship between score variability and clinical outcomes. The expression levels of the 11 genes that are the core of the AlloMap gene expression profiling test were chosen for their performance in linear discriminant analysis for the probability of the presence or absence of acute cellular rejection (4). The changing expression levels of the genes over time in certain circumstances may reflect a change in the status of the recipient’s immune system that is not directly associated with acute cellular rejection. Up until now, the best characterized specific factors that influence background gene expression profiling scores independent of acute cellular rejection include corticosteroid doses above 20 mg/d of prednisone, which is known to suppress the ordinal score, and cytomegalovirus seropositivity of donor and/or recipient, which raises the average ordinal score relative to cytomegalovirus seronegative recipients (11, 12). Race, sex, age, and blood levels of calcineurin inhibitors have relatively minor influence on AlloMap scores (13).

In the future, we may be able to identify further correlations of the gene expression profiling score, its subcomponent genes, and/or score variability to predict more specific events (e.g., morbidity or death from cancer or cardiac allograft vasculopathy). It will be useful to further characterize gene expression profiling score patterns in larger heart transplant cohorts that include more specific categories of clinical end point events collected over longer follow-up periods to confirm and extend the current model findings. The next studies should also determine how variability is affected by the number and time intervals for repeat testing. The Cardiac Allograft Rejection Gene Expression Observational (CARGO II) observational trial and the early IMAGE (EIMAGE) will provide further data on the gene expression profiling score variability associated with earlier (2–6 months posttransplantation) and more frequent (interval of every 2–4 weeks) use of the gene expression profiling test; ClinicalTrials.gov Identifier NCT00761787 and ClinicalTrials.gov Identifier NCT00962377, respectively (14–16).
The further investigation of gene expression profiling scores and score variability on future clinical events is a worthy endeavor because advances in the understanding of the determinants of long-term outcomes have been identified to be among the highest priorities for future heart transplantation research (17).

The small increase in C-index (0.01) when the variability score is added to the base clinical model indicates limited improvement in discrimination of patients who will have events from those who will not have events. However, the 95% confidential intervals range from 0.59 to 0.78, so it is possible that with a larger dataset, a larger difference in the C-index may be demonstrated. The variability factor seems to have promise, based on its highly significant regression coefficient and its favorable AIC score. The clinical utility of the variability score may be assessed based not only on its discrimination performance but also on its calibration performance (agreement between predicted and observed risks across subgroups with varying baseline risk) and/or the new test’s reclassification performance (assessment of the proportion of individuals moved between risk categories relevant to treatment decisions) (18). These additional metrics are beyond the scope of this report.

Our analysis does not distinguish if the variability observed is attributed to a temporal increasing (or decreasing) trend or to variability without a trend. The association of score trends with clinical outcomes has not been anecdotally reported and was not proposed in the main clinical hypothesis of this paper. Trend analyses thus awaits assessment in a future study, where availability of more than four or five test results per patient would enhance the power of the analysis.

Based on the results from the current study, we speculate that independent from the established association of ordinal scores over a threshold value with higher risk of acute cellular rejection at the time of testing, the low variability of a set of gene-expression profiling scores within an individual may be associated with future clinical quiescence in an individual. A low gene expression profiling variability score may predict the clinical stability of an allograft recipient, independent of the fundamental interpretation of single ordinal test scores for risk of acute cellular rejection.

In conclusion, the variability of gene expression profiling scores from an individual may help predict the risk of clinically defined future allograft dysfunction or death in the individual. This prognostic information is independent from and complementary to the original use of single gene expression profiling ordinal test scores to estimate the probability of histologically defined acute cellular rejection at the time of testing. To our knowledge, the current report is the first study of the utility of the variability of a biomarker score that is derived from a multivariable gene expression profile.

Further development and validation of this prognostic test may enable improvement in the long-term management and clinical outcomes of heart transplant recipients.

**MATERIALS AND METHODS**

**Study Design**

The current study was a cohort analysis of patients from the IMAGE study (8). Surveillance visits occurred at 1- and 2-month intervals for patients who were between month 6 and 12 posttransplantation, and at 3-, 4- or 6-month intervals after the first year posttransplantation. The gene expression profiling test (AlloMap) was provided by XDx, Inc., Brisbane, CA (19).

**Patient Population and Surveillance Testing**

The current study cohort, n=369, was drawn from the 662 patients from 13 US centers in the IMAGE study (8). These 369 patients were selected for inclusion because they had at least two gene expression profiling tests before an event or study end, and at least one endomyocardial biopsy and one echocardiogram were included (Fig. 2). During the course of surveillance of this cohort, primary clinical events were documented in 30 patients. Patients in both IMAGE study arms provided blood samples for gene expression profiling studies.

![FIGURE 2. Source of N=369 patients included in the modeling of prediction of future events of allograft failure.](image-url)
expression profiling testing at surveillance visits; samples from both arms of the IMAGE study were included in the current analyses.

**Clinical Events**

The definition of clinical events was taken directly from the IMAGE study. The composite end point was composed of a patient’s first event(s) of the following: rejection with hemodynamic compromise, graft dysfunction due to other causes, death, and/or retransplantation. An independent endpoints committee had adjudicated all primary events (8).

**Statistics**

The association of clinical risk factors with clinical events was assessed in a univariate Cox regression model (R-2.13.1, R foundation, Vienna, Austria). The factors included patient’s race, sex, age at time of transplantation, number of prior rejections in first year, cytomegalovirus serologic status, and time posttransplantation. Age at time of transplant and time posttransplantation were log transformed to better fit the risk of events in these analyses. These factors were selected based on prior published evidence of association with risk of poor allograft outcomes and availability of IMAGE data (8, 20).

The factors that reached significance (P<0.05) in the univariate analyses were included with the gene expression profiling scores in the multivariate Cox proportional hazards models. These models provide a prediction of the risk of future events expressed as a hazard ratio from the gene expression profiling scores, adjusted for the base clinical risk factors. The underlying variable in the Cox regression model was the time since enrollment in the study, rather than time since transplant. This analysis method was selected because, per the IMAGE study protocol inclusion criteria, no patients were enrolled until after 6 months posttransplantation.

The gene expression profiling scores were analyzed in three ways: 1) the ordinal score, an integer ranging from 0 to 39; 2) the threshold score, assigned a binary value of 0 if the ordinal score was less than 34 and assigned a value of 1 if the ordinal score is 34 or higher; and 3) the variability score, which is the standard deviation of all ordinal scores measured within a patient, before incurring a clinical event. The method for computing the variability score is as follows. First, collect the gene expression profiling ordinal scores from the previous visits of an individual: for example, x = 24, 23, 31, and 23. Second, transform each ordinal score by the inverse logit transformation, where for ordinal score x, y = 2.451(log(x/(40-x)) - 0.234) is the transformed score. In the example, y = -0.42, 0.17, 2.5, and 0.17. This transformation is necessary to better satisfy the modeling assumptions of the Cox model. Third, calculate variability score, which is the standard deviation of the transformed scores:

\[ \sigma = \sqrt{\frac{1}{N-1} \sum_{i=1}^{N} (x_i - \mu)^2} \]

where \( x_i \) are the N=4 transformed scores, and \( \mu \) is the mean of the scores. In the example, the variability score is 1.11. The variability score is a time-varying covariate. Beginning with the second visit, one may compute the variability score and use that to predict the risk of events from then until the time of visit 3 or first event, whichever occurs first. If there is no prior event, then at visit 3, one may compute a new variability score based on three ordinal scores to predict an event up to the time of visit 4 (or first event) and so on.

The multivariate models render a regression coefficient and hazard ratio for risk of future events for each of the gene expression profiling score variables, adjusted for the base clinical risk factors. The comparative performance of the three models was assessed by the Akaike information criterion (AIC) and the concordance index (C-index). The AIC is a measure of the estimated information loss in the statistical model; the smaller the AIC, the less is the information loss by the model relative to other models (9). The C-index is a generalization of the area under the receiver operator characteristic curve and measures how well the model performs in predicting future clinical events (21).

**REFERENCES**

19. XDx AlloMap Laboratory Services Guide, LQ10004 revision 1.